This study aimed to evaluate the fibrosis-5 (FIB-5) index as a marker of liver fibrosis for major adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). A total of 406 STEMI patients were enrolled in the study. Over an average follow-up of 27 months, 143 of the patients developed MACE. The patients were subgrouped into tertiles based on the FIB-5 index and Kaplan–Meier survival (MACE-free) curves were plotted, showing statistically significant differences (log-rank test, P < .001). In the adjusted Cox regression model, the hazard ratio (HR) of MACE was 1.95 (95% CI 1.21–3.13; P = .006) in tertile 3 and 0.98 (95% CI 0.97–1.00; P = .013) for per unit increase in the FIB-5 index. The area under the curve (AUC) of the FIB-5 index predicting the occurrence of MACE in STEMI patients after PCI was 0.645 (95% CI 0.590–0.701; P < .001). Low FIB-5 may be a useful predictor of MACE in STEMI patients undergoing PCI.

中文翻译：

---

纤维化 5 指数可预测接受经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的主要不良心血管事件

本研究旨在评估纤维化-5 (FIB-5) 指数作为肝纤维化标志物对接受经皮冠状动脉介入治疗 (PCI) 的 ST 段抬高型心肌梗死 (STEMI) 患者主要不良心血管事件 (MACE) 的影响。共有 406 名 STEMI 患者参加了该研究。在平均 27 个月的随访中，143 名患者出现了 MACE。根据 FIB-5 指数将患者分组为三分位数，并绘制 Kaplan-Meier 生存（无 MACE）曲线，显示统计学显着差异（对数秩检验，P < .001）。在调整后的 Cox 回归模型中，三分位数 3 中 MACE 的风险比 (HR) 为 1.95 (95% CI 1.21–3.13; P = .006)，每组的 MACE 风险比 (HR) 为 0.98 (95% CI 0.97–1.00; P = .013)。 FIB-5 指数单位增加。预测 STEMI 患者 PCI 术后发生 MACE 的 FIB-5 指数的曲线下面积 (AUC) 为 0.645 (95% CI 0.590–0.701；P < .001)。低 FIB-5 可能是接受 PCI 的 STEMI 患者发生 MACE 的有用预测因子。